Edgemont Partners Advises NAMSA on Sale of Majority Stake to ArchiMed
Edgemont closes transaction for the preeminent medical device contract research organization worldwide
NEW YORK, NY – September 22, 2020 – Edgemont Partners (“Edgemont”), an accomplished middle-market healthcare investment bank and leading M&A advisor to outsourced pharmaceutical and medical device services companies, announced that it acted as exclusive financial advisor to NAMSA in its previously reported transaction with ArchiMed, which closed earlier this month. Terms were not disclosed. Edgemont’s deal team included David Blume, Managing Director, Andrew Karlin, VP, Associates David Murphy, Omar Champsi and Philip Litmanov, and John O’Malley, Analyst.
NAMSA is the only full continuum Contract Research Organization (CRO) in the world focused exclusively on medical devices. Founded in 1967, the Company was the first independent company to focus solely on testing medical device materials for safety. Today, NAMSA offers expert medical device testing, regulatory, reimbursement and quality consulting services, and clinical research support to aid clients at every stage of medical device development and beyond. This suite of services is designed to lower development costs and accelerate regulatory approval and commercialization globally for medical device and in vitro diagnostics (IVD) technology sponsors.
ArchiMed is an independent international healthcare private equity investment firm with more than $2 billion under management. ArchiMed’s acquisition of a majority interest in NAMSA is the firm’s second outsourced pharmaceutical and medical device services platform transaction in the U.S. in less than four months. In May, ArchiMed acquired a majority stake in ActiGraph, a leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community based in Pensacola, FL.
NAMSA’s equity recapitalization by ArchiMed is Edgemont’s 22nd outsourced pharmaceutical and medical device services transaction closed in the last 36 months. Other recent transactions include the sale of Research Centers of America to CenExel, Pharmerit’s merger with OPEN Health, the sale of J. Knipper to Court Square Capital Partners, the sale of GCE Solutions to a leading global CRO, and the sale of Regulatory Professionals (RPI) to Premier Research.
Helping medical device sponsors improve healthcare since 1967, NAMSA is the only 100% medical device-focused, full continuum Contract Research Organization (CRO). Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services; NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes.
ArchiMed is an independent investment firm specialized in the Healthcare industries. It is a strategic and financial partner to European and North American companies operating in the Biopharma, Medtech, Diagnostics, Life Sciences, Healthcare IT, Consumer Health, Public Safety and Care Services sectors. ArchiMed’s international team combines investment, medical, technological and operational experience. It works alongside management teams to accelerate their business growth through internationalization, product and service range expansion and capacity extension, both organically and through acquisitions. Over the last 20 years, ArchiMed’s leadership team directly managed and invested in over 40 small, medium and large-size healthcare companies throughout the world, with a combined value above €5 billion. ArchiMed has over €1.7 billion (over $2 billion) under management across three funds, mid-cap-focused MED Platform I, and small-cap-focused MED I and MED II. Its investment capacity currently exceeds €1 billion and rises to twice this amount when including its strategic investment partners.
About Edgemont Partners
Now in its 20th year, Edgemont ranks among the most active and best performing independent healthcare M&A and financial advisors in the U.S. We focus solely on providing expert strategic advice and transaction execution to healthcare and life sciences companies, bringing a steadfast commitment to our clients, driven always to prioritize their best interests. Edgemont’s principals have executed 160+ transactions with an aggregate value of $62 billion+.
Investment banking services are provided by Edgemont Capital Partners, LP, a registered broker-dealer and member of FINRA and SIPC.